Shareholders in Acadia Pharmaceuticals would have breathed a sigh of relief last week when the group finally announced a licensing deal for its lead product, a novel antipsychotic called pimavanserin, with Biovail.
Although not the blue chip name that Acadia had once hinted at, the tiny drug developer is at least now sharing some of the risk, after bravely going it alone for the last few years in pursuit of a higher value deal. With phase III data due in three or four months’ time investors will soon find out whether it was all worth waiting for.
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.